{
    "nctId": "NCT01022333",
    "briefTitle": "The Potential for Oral Diindolylmethane (DIM) Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers",
    "officialTitle": "The Potential for Oral DIM Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 300,
    "primaryOutcomeMeasure": "Oral DIM supplementation increases BRCA1 mRNA expression and hence BRCA1 protein in women with a BRCA1 mutation",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Carriers of a mutation in the BRCA1 gene\n* Non-carriers of a mutation in the BRCA1 gene who come from a family with a BRCA1 mutation (a family in which at least one individual has tested positive for a BRCA1 mutation)\n* Can participate after being free of DIM supplementation for one month\n\nExclusion Criteria:\n\n* Have a personal history of cancer\n* Currently pregnant or breast-feeding",
    "sex": "FEMALE",
    "minimumAge": "25 Years",
    "stdAges": "ADULT"
}